

# CURRICULUM VITAE

---

## Mohammad Majed Abufaraj

Assistant Professor of Urology  
Division of Urology  
Department of Special Surgery  
Faculty of Medicine  
Jordan University Hospital  
The University of Jordan  
Adjunct Professor of Urology  
Medical University of Vienna  
Chief Co-Editor  
Arab Journal of Urology (Arab J Urol)  
Tel. (+962) 799668669  
mabufaraj@ju.edu.jo  
dr.abufaraj@gmail.com

### PERSONAL DETAILS

---

Date of Birth: March 28, 1985  
Place of Birth: Aqaba, Jordan  
Nationality: Jordanian  
Gender: Male

### EDUCATION

---

<b>Medical University of Vienna, Vienna, Austria</b> Clinical fellowship \Urologic oncology	<i>March 2019</i>
<b>Medical University of Vienna, Vienna, Austria</b> Clinical research fellowship \Urologic oncology	<i>March 2017</i>
<b>Jordan University of Science and Technology, Irbid, Jordan</b> Higher Specialty in Medicine \Urology	<i>June 2015</i>
<b>Jordan University of Science and Technology, Irbid, Jordan</b> M.BSc. of Medicine & Surgery (MBBS)	<i>June 2009</i>
<b>Aqaba Secondary School, Jordan</b> General Secondary Certificate (Scientific Branch)	<i>August 2003</i>

### POST GRADUATE EDUCATION, TRAINING AND EMPLOYMENT

---

<b>Adjunct Professor of Urology</b> <i>Department of Urology, Medical University of Vienna, Vienna, Austria</i>	<i>January 2021- now</i>
An honorary appointment by The Medical University of Vienna in recognition of scientific contribution and collaboration with the Department of Urology.	
<b>Assistant Professor of Urology</b> <i>Division of Urology, Department of Special Surgery, School of Medicine, The University of Jordan, Amman, Jordan</i>	<i>April 2019- now</i>

Full-time academic staff in the School of Medicine at the University of Jordan. The teaching duties are carried out at Jordan University Hospital the main hospital affiliated with the School of Medicine at the The University of Jordan. Urology is a mandatory rotation for medical students in their fifth year and they are evaluated by end-rotation exam, and eventually by final written exam.

**Consultant Urologist**

*April 2019- now*

*Division of Urology, Department of Special Surgery, Jordan University Hospital, Amman, Jordan*

Full-Time Consultant Urologist dealing with a wide range of urological conditions with special interest in urologic oncology.

**Part-Time Consultant Urologist**

*December 2019- now*

*The National Center for Diabetes Endocrinology and Genetics*

Part-Time Consultant Urologist treating patients at the The National Center for Diabetes Endocrinology and Genetics.

**Clinical fellowship**

*March 2017- March 2019*

*Vienna General Hospital, Medical university of Vienna, Vienna, Austria*

Two year clinical fellowship in urologic oncology under the supervision of Professor Shahrokh F. Shariat in Vienna General Hospital.

**Clinical research fellowship**

*March 2016- March 2017*

*Vienna General Hospital, Medical university of Vienna, Vienna, Austria*

One year in clinical research under the supervision of Professor Shahrokh F. Shariat who is one of the leading onco-urologists worldwide and unique expertise in urological malignancy especially bladder cancer research.

**Specialist and teaching assistant**

*December 2015- March 2016*

*Jordan University Hospital (JUH), Amman, Jordan*

A specialist the department of urology, The university of Jordan and teaching assistant in the Faculty of Medicine, The university of Jordan.

**Residency training program in urology**

*June 2010- June 2015*

*King Abdullah University Hospital (KAUH), Irbid, Jordan*

Training was comprised of a preliminary general surgery year followed by four-years structured training in urology. The department of urology at (KAUH) provides excellent exposure to a wide breadth of urologic disorders. The department runs a relatively busy clinical service.

**Intermediate PCR (Polymerase chain reaction) course**

*December 2013*

*Jordan university of science and technology, Irbid, Jordan*

This course was sponsored by biosecurity engagement program, US Department of State, delivered by Princess Haya Biotechnology Center - Jordan University of Science and Technology and International Biological Threat Reduction Sandia International laboratories.

**Basic PCR (Polymerase Chain Reaction) course**

*August 2013*

*Jordan University of Science and Technology, Irbid, Jordan*

This course was sponsored by biosecurity engagement program, US Department of State, delivered by Princess Haya Biotechnology Center - Jordan University of Science and Technology and International Biological Threat Reduction Sandia International laboratories.

**Basic Life Support (BLS) For Healthcare Providers**

*February 2012*

*Operation Smile Training Center, Amman, Jordan*

King Abdullah University Hospital, Irbid, Jordan

In accordance with the curriculum of the American Heart Association.

**Internship for the purpose of medical practice licensure**  
*Royal Medical Services, Princess Haya Hospital, Aqaba, Jordan*

*June 2009- June 2010*

- One year internship

**Advanced Cardiovascular Life Support (ACLS)**  
*Operation Smile Training Center, Amman, Jordan*

*August 2009*

In accordance with the curriculum of the American Heart Association.

## MEDICAL LICENSURES

---

- BSAFE certificate by the United Nations Department of Safety and Security.
- Certificate of Good Clinical Practice (GCP) in collaboration with the National Institute on Drug Abuse (NIDA) Center for Clinical Trials (CCTN) Clinical Trials Network (CTN) *April 2020*
- Medical practice licensure in Austria. *March 2016*
- Jordan medical Council Urology Board Exam (Jordanian Board of Urology). *August 2015*
- Membership of Royal College of Surgeons in Ireland (MRCSI), Part A. *September 2013*
- Medical practice licensure in Jordan. *June 2010*

## PUBLICATIONS

---

1. Cytoreductive Surgery in Patients with Urothelial Bladder Cancer  
**Abufaraj M**, Li R, Meeks J, Shariat SF.  
**Eur Urol Focus.** 2022 Dec 9:S2405-4569(22)00283-8. doi: 10.1016/j.euf.2022.11.020.  
PMID: 36509654  
Impact factor: 5.9
2. Oncologic Impact of Cystoscopic Findings in Non-Muscle Invasive Bladder Cancer: A Meta-analysis  
Yanagisawa T, Quhal F, Kawada T, Mostafaei H, Sari Motlagh R, Laukhtina E, Rajwa P, von Deimling M, Bianchi A, Pallauf M, Majdoub M, Pradere B, **Abufaraj M**, Moschini M, Karakiewicz PI, Iwatani K, Miki J, Kimura T, Shariat SF.  
**BJU Int.** 2022 Dec 7. doi: 10.1111/bju.15944.  
PMID: 36479820  
Impact factor: 5.9
3. Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis  
Mori K, Yanagisawa T, Katayama S, Laukhtina E, Pradere B, Mostafaei H, Quhal F, Rajwa P, Moschini M, Soria F, D'andrea D, **Abufaraj M**, Albisinni S, Krajewski W, Fukuokaya W, Miki J, Kimura T, Egawa S, Teoh JY, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).  
**World J Urol.** 2022 Aug 13. doi: 10.1007/s00345-022-04116-x.

PMID: 35963957

Impact factor: 2.9

4. Prevalence and trends of urolithiasis among adults

**Abufaraj M**, Al Karmi J, Yang L.

**Curr Opin Urol.** 2022 Jun 9. doi: 10.1097/MOU.0000000000000994.

PMID: 35703251

Impact factor: 2.2

5. ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy

Mori K, Schuettfort VM, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, Teoh JYC, Resch I, Fajkovic H, Moschini M, D'andrea D, **Abufaraj M**, Karakiewicz PI, Lotan Y, Scherr D, Egawa S, Comp erat E, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).

**Ann Surg Oncol.** 2022 May 9. doi: 10.1245/s10434-022-11742-7.

PMID: 35532830

Impact factor: 5.3

6. Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study

Grossmann NC, Rajwa P, Quhal F, K onig F, Mostafaei H, Laukhtina E, Mori K, Katayama S, Motlagh RS, Fankhauser CD, Mattei A, Moschini M, Chlosta P, van Rhijn BWG, Teoh JYC, Comp erat E, Babjuk M, **Abufaraj M**, Karakiewicz PI, Shariat SF, Pradere B.

**Eur Urol Open Sci.** 2022 Apr 1;39:14-21. doi: 10.1016/j.euros.2022.02.011. eCollection 2022 May.

PMID: 35528782

7. Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis

Aydh A, Motlagh RS, **Abufaraj M**, Mori K, Katayama S, Grossmann N, Rajawa P, Mostafai H, Laukhtina E, Pradere B, Quhal F, Schuettfort VM, Briganti A, Karakiewicz PI, Fajkovic H, Shariat SF.

**Arab J Urol.** 2022 Mar 30;20(2):71-80. doi: 10.1080/2090598X.2022.2026010. eCollection 2022.

PMID: 35530569

8. Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy

Sari Motlagh R, Schuettfort VM, Mori K, Katayama S, Rajwa P, Aydh A, Grossmann NC, Laukhtina E, Pradere B, Mostafai H, Quhal F, **Abufaraj M**, Lee R, Karakiewicz PI, Lotan Y, Comprate E, Moschini M, Gontero P, Shariat SF.

**Int J Urol.** 2022 Apr 2. doi: 10.1111/iju.14869.

PMID: 35368130

Impact factor: 2.4

9. Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy

Mori K, Schuettfort VM, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, Teoh JY, Resch I, Fajkovic H, Moschini M, D'andrea D, **Abufaraj M**, Karakiewicz PI, Lotan Y, Scherr D, Egawa S, Comp erat E, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).

**Ann Surg Oncol.** 2022 Mar 26. doi: 10.1245/s10434-022-11575-4.

PMID: 35347517

Impact factor: 4.2

10. Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group

Laukhtina E, Moschini M, Soria F, Andrea DD, Teoh JY, Mori K, Albisinni S, Mari A, Krajewski W, Cimadamore A, **Abufaraj M**, Enikeev D, Neuzillet Y, Giannarini G, Xylinas E, Kamat AM, Roupret M, Babjuk M, Witjes JA, Shariat SF, Pradere B; European Association of Urology; Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group; European Association of Urology Section of Oncological Urology ESOU.

**Eur Urol Focus.** 2022 Mar 22:S2405-4569(22)00058-X. doi: 10.1016/j.euf.2022.03.004.

PMID: 35337773

Impact factor: 4.8

11. Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis

Mori K, Schuettfort VM, Yanagisawa T, Katayama S, Pradere B, Laukhtina E, Rajwa P, Mostafaei H, Sari Motlagh R, Quhal F, Moschini M, Soria F, Teoh JYC, D'Andrea D, **Abufaraj M**, Albisinni S, Krajewski W, Egawa S, Karakiewicz PI, Rink M, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).

**Eur Urol Focus.** 2022 Mar 9:S2405-4569(22)00052-9. doi: 10.1016/j.euf.2022.02.007.

PMID: 35279408

Impact factor: 4.8

12. Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study

Grossmann NC, Pradere B, D'Andrea D, Schuettfort VM, Mori K, Rajwa P, Quhal F, Laukhtina E, Katayama S, Fankhauser CD, Xylinas E, Margulis V, Moschini M, **Abufaraj M**, Bandini M, Lonati C, Nyirady P, Karakiewicz PI, Fajkovic H, Shariat SF.

**Clin Genitourin Cancer.** 2022 Jan 11:S1558-7673(22)00004-0. doi: 10.1016/j.clgc.2022.01.004.

PMID: 35125303

Impact factor: 2.7

13. The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy  
Martini A, Lonati C, Montorsi F, Briganti A, Colombo R, Necchi A, Simeone C, Zamboni S, Afferi L, Mattei A, Carando R, Ploussard G, Soria F, Marra G, Rouprêt M, Xylinas E, Pradere B, **Abufaraj M**, D'Andrea D, Shariat SF, Moschini M.  
**Clin Genitourin Cancer.** 2021 Dec 11:S1558-7673(21)00236-6. doi: 10.1016/j.clgc.2021.12.006.  
PMID: 35105509  
Impact factor: 2.7
14. Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer  
Katayama S, Schuettfort VM, Pradere B, Mori K, Mostafaei H, Quhal F, Sari Motlagh R, Laukhtina E, Grossmann NC, Aydh A, Rajwa P, König F, Karakiewicz PI, Haydter M, Moschini M, **Abufaraj M**, Lotan Y, Lee RK, Trinh QD, Compérat E, Teoh J, Nasu Y, Shariat SF.  
**J Cancer Res Clin Oncol.** 2022 Jan 8. doi: 10.1007/s00432-021-03887-x.  
PMID: 34997350  
Impact factor: 4.55
15. Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy  
Grossmann NC, Schuettfort VM, Pradere B, Rajwa P, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Aydh A, Katayama S, Moschini M, Fankhauser CD, Hermanns T, **Abufaraj M**, Mun DH, Zimmermann K, Fajkovic H, Haydter M, Shariat SF.  
**Urol Oncol.** 2021 Nov 20:S1078-1439(21)00474-9. doi: 10.1016/j.urolonc.2021.10.006.  
PMID: 34810077  
Impact factor: 3.01
16. Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma  
Mori K, Katayama S, Laukhtina E, Schuettfort VM, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, Zimmermann K, Karakiewicz PI, **Abufaraj M**, Fajkovic H, Rouprêt M, Margulis V, Enikeev DV, Egawa S, Shariat SF.  
**Clin Genitourin Cancer.** 2021 Oct 10:S1558-7673(21)00192-0. doi: 10.1016/j.clgc.2021.10.002.  
PMID: 34764007  
Impact factor: 2.7
17. Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder  
Laukhtina E, Schuettfort VM, D Andrea D, Pradere B, Mori K, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann N, Rajwa P, Zeinler F, **Abufaraj M**, Moschini M, Zimmermann K, Karakiewicz PI, Fajkovic H, Scherr D, Compérat E, Nyirady P, Rink M, Enikeev D, Shariat SF.  
**Mol Carcinog.** 2021 Sep 29. doi: 10.1002/mc.23355.  
PMID: 34587660  
Impact factor: 4.7

18. Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis  
Sari Motlagh R, **Abufaraj M**, Karakiewicz PI, Rajwa P, Mori K, Mun DH, Shariat SF.  
**World J Urol.** 2021 Sep 3:1-8. doi: 10.1007/s00345-021-03810-6.  
PMID: 34477955  
Impact factor: 2.8
19. Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis  
Laukhtina E, Mori K, D Andrea D, Moschini M, **Abufaraj M**, Soria F, Mari A, Krajewski W, Albisinni S, Teoh JY, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann N, Rajwa P, Enikeev D, Zimmermann K, Fajkovic H, Glybochko P, Shariat SF, Pradere B; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).  
**Urol Oncol.** 2021 Jul 12:S1078-1439(21)00267-2. doi: 10.1016/j.urolonc.2021.06.009.  
PMID: 34266740  
Impact factor: 3.01
20. The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials  
Sari Motlagh R, **Abufaraj M**, Mori K, Aydh A, Rajwa P, Katayama S, Grossmann NC, Laukhtina E, Mostafai H, Pradere B, Quhal F, Karakiewicz PI, Enikeev DV, Shariat SF.  
**Eur Urol Oncol.** 2021 Jul 20:S2588-9311(21)00122-X. doi: 10.1016/j.euo.2021.07.002.  
PMID: 34192006  
Impact factor: 7.47
21. Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy  
Aydh A, Mori K, D'Andrea D, Motlagh RS, **Abufaraj M**, Pradere B, Mostafaei H, Laukhtina E, Quhal F, Karakiewicz PI, Luzzago S, Briganti A, Trinh QD, Parizi MK, Tilki D, Enikeev DV, Shariat SF.  
**Int J Clin Oncol.** 2021 Jun 28. doi: 10.1007/s10147-021-01952-6.  
PMID: 34184136  
Impact factor: 2.8
22. Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes After Radical Cystectomy  
Schuetfort VM, Pradere B, D'Andrea D, Grossmann NC, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, Karakiewicz PI, Motlagh RS, Katayama S, Lotan Y, Scherr D, **Abufaraj M**, Fajkovic H, Compérat E, Enikeev D, Shariat SF.  
**J Urol.** 2021 Jun 28:101097JU0000000000001936. doi: 10.1097/JU.0000000000001936.  
PMID: 34181469  
Impact factor: 5.6

23. Systemic Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Network Meta-Analysis  
Mori K, Mostafaei H, Sari Motlagh R, Pradere B, Quhal F, Laukhtina E, Schuettfort VM, Kramer G, **Abufaraj M**, Karakiewicz PI, Kimura T, Egawa S, Shariat SF.  
**BJU Int.** 2021 Jun 25. doi: 10.1111/bju.15507.  
PMID: 34171173  
Impact factor: 4.8
24. Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer  
Katayama S, Mori K, Pradere B, Laukhtina E, Schuettfort VM, Quhal F, Motlagh RS, Mostafaei H, Grossmann NC, Rajwa P, Moschini M, Mathieu R, **Abufaraj M**, D'Andrea D, Comp erat E, Haydter M, Egawa S, Nasu Y, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).  
**World J Urol.** 2021 Jun 18. doi: 10.1007/s00345-021-03740-3.  
PMID: 34143284  
Impact factor: 2.8
25. Diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study  
Farah RI, Al-Sabbagh MQ, Momani MS, Albtoosh A, Arabiat M, Abdulraheem AM, Aljabiri H, **Abufaraj M**  
**BMC Nephrol.**2021 Jun 16;22(1):223. doi: 10.1186/s12882-021-02429-4.  
PMID: 34134654  
Impact factor: 2.1
26. Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis  
Laukhtina E, Rajwa P, Mori K, Moschini M, D'Andrea D, **Abufaraj M**, Soria F, Mari A, Krajewski W, Albisinni S, Teoh JY, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Enikeev D, Zimmermann K, Fajkovic H, Glybochko P, Shariat SF, Pradere B; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group (EAU YAU).  
**Eur Urol Focus.**2021 Jun 11:S2405-4569(21)00162-0. doi: 10.1016/j.euf.2021.05.010.  
PMID: 34127436  
Impact factor: 4.8
27. Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer  
Mori K, Sharma V, Comperat EM, Sato S, Laukhtina E, Schuettfort VM, Pradere B, Sari Motlagh R, Mostafaei H, Quhal F, Kardoust Parizi M, **Abufaraj M**, Karakiewicz PI, Egawa S, Tilki D, Boorjian SA, Shariat SF.  
**Ann Surg Oncol.** 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.  
PMID: 34117577  
Impact factor: 4.2
28. Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder



Schuetfort VM, Gust K, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, **Abufaraj M**, Karakiewicz PI, Luzzago S, Rouprêt M, Enikeev D, Zimmermann K, Deuker M, Moschini M, Sari Motlagh R, Grossmann NC, Katayama S, Pradere B, Shariat SF.

**Minerva Urol Nephrol.** 2021 Jun 11. doi: 10.23736/S2724-6051.21.04216-6.

PMID: 34114784

Impact factor: 3.5

29. Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers

Albisinni S, Moschini M, Di Trapani E, Soria F, Mari A, Aziz A, Teoh J, Laukhtina E, Mori K, D'Andrea D, Carrion DM, Krajewski W, **Abufaraj M**, Cimadamore A, Tan WS, Flippot R, Khalifa J, Gonsette K, Pradere B; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).

**World J Urol.** 2021 Jun 2. doi: 10.1007/s00345-021-03746-x.

PMID: 34076754

Impact factor: 2.8

30. The combinatorial use of propofol-fentanyl-ketamine for sedoanalgesia in patients undergoing urological procedures

Aloweidi AS, Abu-Halaweh SA, Al-Edwan GM, Al Demour SH, Abu Mahfuz LT, Noubani ON, Al Rwaidi MM, Bsisu IK, **Abufaraj M**

**Saudi Med J.** 2021 Jun;42(6):629-635. doi: 10.15537/smj.2021.42.6.20210071.

PMID: 34078724

Impact factor: 1

31. Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma

Katayama S, Mori K, Schuetfort VM, Pradere B, Mostafaei H, Quhal F, Rajwa P, Motlagh RS, Laukhtina E, Moschini M, Grossmann NC, Araki M, Teoh JY, Rouprêt M, Margulis V, Enikeev D, Karakiewicz PI, **Abufaraj M**, Compérat E, Nasu Y, Shariat SF.

**Eur Urol Focus.** 2021 May 27:S2405-4569(21)00154-1. doi: 10.1016/j.euf.2021.05.002.

PMID: 34053904

Impact factor: 4.8

32. Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review

Laukhtina E, Sari Motlagh R, Mori K, Quhal F, Schuetfort VM, Mostafaei H, Katayama S, Grossmann NC, Ploussard G, Karakiewicz PI, Briganti A, **Abufaraj M**, Enikeev D, Pradere B, Shariat SF.

**World J Urol.** 2021 May 28:1-15. doi: 10.1007/s00345-021-03703-8.

PMID: 34047825

Impact factor: 2.8

33. Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer

Schuettfort VM, Pradere B, Trinh QD, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Karakiewicz PI, Chlosta P, Yuen-Chun Teoh J, Lotan Y, Scherr D, **Abufaraj M**, Moschini M, Shariat SF.

**Cancer Immunol Immunother.** 2021 May 23. doi: 10.1007/s00262-021-02953-0.

PMID: 34023914

Impact factor: 4.9

34. Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study

Foerster B, **Abufaraj M**, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Marcq G, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffelle V, Kassouf W, Autorino R, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF.

**Eur Urol.** 2021 May 19:S0302-2838(21)00328-6. doi: 10.1016/j.eururo.2021.05.004.

PMID: 34023164

Impact factor: 18.7

35. Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review

Schuettfort VM, Pradere B, Compérat E, **Abufaraj M**, Shariat SF.

**Curr Opin Urol.** 2021 May 10. doi: 10.1097/MOU.0000000000000892.

PMID: 33973535

Impact factor: 2.2

36. Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review

Laukhtina E, Pradere B, Mori K, Schuettfort VM, Quhal F, Mostafaei H, Sari Motlagh R, Aydh A, Moschini M, Enikeev D, Karakiewicz PI, **Abufaraj M**, Shariat SF; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group.

**Urol Oncol.** 2021 Apr 19:S1078-1439(21)00115-0. doi: 10.1016/j.urolonc.2021.03.005.

PMID: 33888424

Impact factor: 2.9

37. Gender-based disparities on health indices during COVID-19 crisis: a nationwide cross-sectional study in Jordan

**Abufaraj M**, Eyadat Z, Al-Sabbagh MQ, Nimer A, Moonesar IA, Yang L, Al Khatib W, Al-Qutob R.

**Int J Equity Health.** 2021 Apr 6;20(1):91. doi: 10.1186/s12939-021-01435-0.

PMID: 33823852

Impact factor: 2.8

38. Detection of Urothelial Bladder Cancer Based on Urine and Tissue Telomerase Activity Measured by Novel RT-TRAP-2PCR Method

Glukhov A, Potoldykova N, Taratkin M, Gordeev S, Polyakovsky K, Laukhtina E, Moschini M, **Abufaraj M**, Shariat SF, Sekacheva M, Enikeev D, Glybochko P.

**J Clin Med.** 2021 Mar 4;10(5):1055. doi: 10.3390/jcm10051055.

PMID: 33806392

Impact factor: 5.6

39. Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study

Marcq G, Foerster B, **Abufaraj M**, Marin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffelle V, Autorino R, John P, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF, Kassouf W.

**Eur Urol Focus.** Mar 24:S2405-4569(21)00097-3. doi: 10.1016/j.euf.2021.03.018.

PMID: 33773965

Impact factor: 4.8

40. Association Between Body Fat Mass and Kidney Stones in US Adults: Analysis of the National Health and Nutrition Examination Survey 2011-2018

**Abufaraj M**, Siyam A, Xu T, Imm K, Cao C, Waldoer T, Schernhammer E, Shariat SF, Yang L.

**Eur Urol Focus.** 2021 Mar 15:S2405-4569(21)00067-5. doi: 10.1016/j.euf.2021.03.010.

PMID: 33737023

Impact factor: 4.8

41. Prevalence and Trends in Urinary Incontinence Among Women in the United States 2005-2018

**Abufaraj M**, Xu T, Cao C, Siyam A, Isleem U, Massad A, Soria F, Shariat SF, Sutcliffe S, Yang L.

**Am J Obstet Gynecol.** 2021 Mar 13:S0002-9378(21)00168-X. doi: 10.1016/j.ajog.2021.03.016.

PMID: 33727114

Impact factor: 6.5

42. Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence

Laukhtina E, **Abufaraj M**, Al-Ani A, Ali MR, Mori K, Moschini M, Quhal F, Sari Motlagh R, Pradere B, Schuettfort VM, Mostafaei H, Katayama S, Grossmann NC, Fajkovic H, Soria F, Enikeev D, Shariat SF; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group.

**Eur Urol Focus.** 2021 Mar 21:S2405-4569(21)00095-X. doi: 10.1016/j.euf.2021.03.016.

PMID: 33762203

Impact factor: 4.8

43. Surgical intervention in patients with urothelial carcinoma of the bladder and lymph node metastasis

**Abufaraj M**, Al-Ani A, AlQudah A, Shariat SF.

**Curr Opin Urol.** 2021 Mar 10. doi: 10.1097/MOU.0000000000000866.

PMID: 33742983

Impact factor: 2.15

44. Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review

Aydh A, **Abufaraj M**, Mori K, Quhal F, Pradere B, Motlagh RS, Mostafaei H, Karakiewicz PI, Shariat SF.

**Arab J Urol.** 2020 Dec 10;19(1):59-66. doi: 10.1080/2090598X.2020.1858012.

PMID: 33763249

45. Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis

Moschini M, Zamboni S, Afferi L, Pradere B, **Abufaraj M**, Soria F, D'Andrea D, Roupret M, De la Taille A, Simeone C, Mattei A, Mathieu R, Bensalah K, Wirth MP, Montorsi F, Briganti A, Gallina A, Simone G, Gallucci M, Di Bona C, Marra G, Mari A, Di Trapani E, Alvarez Maestro M, Krajewski W, Shariat SF, Xylinas E, Baumeister P.

**Arab J Urol.** 2020 Sep 4;19(1):31-36. doi: 10.1080/2090598X.2020.1817720.

PMID: 33763246

46. Is There an Oncological Benefit of Performing Bilateral Pelvic Lymph Node Dissection in Patients with Penile Cancer and Inguinal Lymph Node Metastasis?

Suarez-Ibarrola R, Basulto-Martinez M, Sigle A, **Abufaraj M**, Gratzke C, Miernik A.

**J Clin Med.** 2021 Feb 13;10(4):754. doi: 10.3390/jcm10040754.

PMID: 33668548

Impact factor: 3.3

47. A Panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma

Schuetthfort VM, Andrea DD, Quhal F, Mostafaei H, Laukhtina E, Mori K, König F, Rink M, **Abufaraj M**, Karakiewicz PI, Luzzago S, Rouprêt M, Enikeev D, Zimmermann K, Deuker M, Moschini M, Sari Motlagh R, Grossmann NC, Katayama S, Pradere B, Shariat SF.

**BJU Int.** 2021 Mar 1. doi: 10.1111/bju.15379.

PMID: 33650265

Impact factor: 4.8

48. Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration

Mori K, Resch I, Miura N, Laukhtina E, Schuetthfort VM, Pradere B, Katayama S, D'Andrea D, Kardoust Parizi M, **Abufaraj M**, Fukuokaya W, Collà Ruvolo C, Luzzago S, Knipper S, Palumbo C, Karakiewicz PI, Briganti A, Enikeev DV, Rouprêt M, Margulis V, Egawa S, Shariat SF.

**Cancer Immunol Immunother.** 2021 Feb 16. doi: 10.1007/s00262-021-02884-w.

PMID: 33591412

Impact factor: 4.9

49. Burnout Syndrome during Residency Training in Jordan: Prevalence, Risk Factors, and Implications

Nimer A, Naser S, Sultan N, Alasad RS, Rabadi A, Abu-Jubba M, Al-Sabbagh MQ, Jaradat KM, AlKayed Z, Aborajooch E, Daradkeh S, **Abufaraj M**.

**Int J Environ Res Public Health**. 2021 Feb 6;18(4):1557. doi: 10.3390/ijerph18041557.

PMID: 33562100

Impact factor: 2.8

50. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer

Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuettfort VM, Karakiewicz PI, Rouprêt M, Enikeev D, Rink M, **Abufaraj M**, Shariat SF.

**World J Urol**. 2021 Jan 26. doi: 10.1007/s00345-020-03586-1.

PMID: 33496841

Impact factor: 2.9

51. Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets

Grossmann NC, Schuettfort VM, Pradere B, Moschini M, Quhal F, Mostafaei H, Soria F, Katayama S, Laukhtina E, Mori K, Sari Motlagh R, Poyet C, **Abufaraj M**, Karakiewicz PI, Shariat SF, D'Andrea D.

**Onco Targets Ther**. 2021 Jan 13;14:315-324. doi: 10.2147/OTT.S242248. eCollection 2021.

PMID: 33488094

Impact factor: 3

52. Functional Outcomes after Local Salvage Therapies for Radiation-Recurrent Prostate Cancer Patients: A Systematic Review

**Abufaraj M**, Siyam A, Ali MR, Suarez-Ibarrola R, Yang L, Foerster B, Shariat SF.

**Cancers (Basel)**. 2021 Jan 11;13(2):E244. doi: 10.3390/cancers13020244.

PMID: 33440752

Impact factor: 6.2

53. Penile Rehabilitation Strategy after the Nerve-Sparing Radical Prostatectomy: A Systematic Review and Network meta-Analysis of Randomized Trials

Motlagh RS, **Abufaraj M**, Yang L, Mori K, Pradere B, Laukhtina E, Mostafaei H, Schuettfort V, Quhal F, Montorsi F, Amjadi M, Gratzke C, Shariat SF.

**J Urol**. 2021 Jan 14:101097JU0000000000001584. doi: 10.1097/JU.0000000000001584.

PMID: 33443457

Impact factor: 5.6

54. A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis

Afferi L, **Abufaraj M**, Soria F, D'Andrea D, Xylinas E, Seisen T, Roupret M, Lonati C, De la Taille A, Peyronnet B, Laukhtina E, Pradere B, Mari A, Krajewski W, Alvarez-Maestro M, Kikuchi E, Shigeta K, Chlosta P, Montorsi F, Briganti A, Simone G, Ornaghi PI, Cerruto MA, Antonelli A, Matsumoto K, Karakiewicz PI, Mordasini L, Mattei A, Shariat SF, Moschini M.

**Minerva Urol Nefrol.** 2021 Jan 13. doi: 10.23736/S0393-2249.20.04127-2.

PMID: 33439575

Impact factor: 3.5

55. Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic  
Hashem H, **Abufaraj M**, Tbakhi A, Sultan I.

**Front Med (Lausanne)** 2020 Dec 23;7:598038. doi: 10.3389/fmed.2020.598038. eCollection 2020.

PMID: 33425945

Impact factor: 3

56. Predictors of adherence with home quarantine during COVID-19 crisis: the case of health belief model

Al-Sabbagh MQ, Al-Ani A, Mafrachi B, Siyam A, Isleem U, Massad FI, Alsabbagh Q, **Abufaraj M**

**Psychol Health Med.** 2021 Jan 11:1-13. doi: 10.1080/13548506.2021.1871770.

PMID: 33427487

Impact factor: 1.6

57. Association of erectile dysfunction and cardiovascular diseases: an umbrella review of systematic reviews and meta-analyses

Mostafaei H, Mori K, Hajebrahimi S, **Abufaraj M**, Karakiewicz PI, Shariat SF.

**BJU Int.** 2020 Dec 1. doi: 10.1111/bju.15313.

PMID: 33260254

Impact factor: 4.8

58. Impact of Preoperative Serum Albumin-Globulin Ratio on Disease Outcome After Radical Cystectomy for Urothelial Carcinoma of the Bladder

Schuetfort VM, D Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, **Abufaraj M**, Karakiewicz PI, Luzzago S, Roupret M, Chlosta P, Babjuk M, Deuker M, Moschini M, Shariat SF, Pradere B.

**Urol Oncol.** 2020 Nov 11:S1078-1439(20)30574-3. doi: 10.1016/j.urolonc.2020.11.005.

PMID: 33189530

Impact factor: 2.9

59. Inflammatory Bowel Disease and Prostate Cancer Risk: A systematic review

Haddad A, Al-Sabbagh MQ, Al-Ani H, Siyam AM, Aborajooch E, Iwata T, Kimura S, Shariat SF, **Abufaraj M**,

**Arab J Urol.** 2020 May 19;18(4):207-212. doi: 10.1080/2090598X.2020.1761674.

PMID: 33312730

60. The significance of De Ritis ratio in patients with radiation-recurrent prostate cancer undergoing salvage radical prostatectomy

Quhal F, **Abufaraj M**, Janisch F, Mori K, Lysenko I, Mostafaei H, D'Andrea D, Mathieu R, Enikeev DV, Fajkovic H, Heidenreich A, Shariat SF.

**Arab J Urol.** 2020 May 31;18(4):213-218. doi: 10.1080/2090598X.2020.1771947.

PMID: 33312731

61. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis

Mori K, **Abufaraj M**, Mostafaei H, Quhal F, Fajkovic H, Remzi M, Karakiewicz PI, Egawa S, Schmidinger M, Shariat SF, Gust KM.

**Eur Urol.** 2020 Nov 7:S0302-2838(20)30783-1. doi: 10.1016/j.eururo.2020.10.006.

PMID: 33172722

Impact factor: 17.9

62. The impact of the COVID-19 pandemic on mental health: early quarantine-related anxiety and its correlates among Jordanians

Massad I, Al-Taher R, Massad F, Al-Sabbagh MQ, Haddad M, **Abufaraj M**.

**East Mediterr Health J.** 2020 Oct 13;26(10):1165-1172. doi: 10.26719/emhj.20.115.

PMID: 33103743

Impact factor: 0.69

63. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma

Pradere B, D'Andrea D, Schuettfort VM, Foerster B, Quhal F, Mori K, **Abufaraj M**, Margulis V, Deuker M, Briganti A, Mulwijk T, Hendricksen K, Lotan Y, Karakiewicz P, F Shariat S; UTUC collaboration.

**World J Urol.** 2020 Oct 16. doi: 10.1007/s00345-020-03479-3.

PMID: 33067726

Impact factor: 2.8

64. Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma

Schuettfort VM, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Rink M, D'Andrea D, **Abufaraj M**, Karakiewicz PI, Shariat SF.

**Turk J Urol.** 2020 Oct 9. doi: 10.5152/tud.2020.20392.

PMID: 33052841

65. The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC)

Foerster B, **Abufaraj M**, Mari A, Seisen T, Bandini M, Schweitzer D, Czech AK, Moschini M, D'Andrea D, Bianchi M, Hendricksen K, Rouprêt M, Briganti A, van Rhijn BWG, Chłosta P, Colin P, John H, Shariat SF.

- Clin Genitourin Cancer.** 2020 Sep 18:S1558-7673(20)30218-4. doi: 10.1016/j.clgc.2020.09.002.  
PMID: 33046411  
Impact factor: 2.7
66. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis  
Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, **Abufaraj M**, Karakiewicz PI, Kimura T, Egawa S, Shariat SF.  
**Int J Clin Oncol.** 2020 Sep 14. doi: 10.1007/s10147-020-01777-9.  
PMID: 32924096  
Impact factor: 2.5
67. Prevalence and Trends in Kidney Stone Among Adults in the USA: Analyses of National Health and Nutrition Examination Survey 2007-2018 Data  
**Abufaraj M**, Xu T, Cao C, Waldhoer T, Seitz C, D'andrea D, Siyam A, Tarawneh R, Fajkovic H, Schernhammer E, Yang L, Shariat SF.  
**Eur Urol Focus.** 2020 Sep 5:S2405-4569(20)30224-8. doi: 10.1016/j.euf.2020.08.011.  
PMID: 32900675  
Impact factor: 4.8
68. Does severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cause orchitis in patients with coronavirus disease 2019 (COVID-19)?  
Alkhatatbeh H, Alzaghari D, Alkhashman A, Azab M, Edwan GMA, **Abufaraj M**.  
**Arab J Urol.** 2020 Aug 11;18(3):129-133. doi: 10.1080/2090598X.2020.1798862.  
PMID: 33029419  
Impact factor: ESCI
69. Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC)  
Laukhtina E, Mostafaei H, D'Andrea D, Pradere B, Quhal F, Mori K, Miura N, Schuettfort VM, Sari Motlagh R, Aydh A, **Abufaraj M**, Karakiewicz PI, Enikeev D, Kimura S, Shariat SF.  
**World J Urol.** 2020 Aug 17. doi: 10.1007/s00345-020-03384-9.  
PMID: 32808107  
Impact factor: 2.8
70. The Association Between Personality Traits and Specialty Preference Among Medical Students in Jordan  
Nawaiseh MB, Haddadin RR, Al Droubi B, Nawaiseh HB, Alarood S, Aborajooch E, **Abufaraj M**, Abu-Yaghi NE.  
**Psychol Res Behav Manag.** 2020 Jul 24;13:599-607. doi: 10.2147/PRBM.S262062.  
PMID: 32801957  
Impact factor: 2



71. Primary Ta high grade bladder tumors: Determination of the risk of progression  
Quhal F, D'Andrea D, Soria F, Moschini M, **Abufaraj M**, Rouprêt M, Karakiewicz PI, Yang L, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Shariat SF.  
**Urol Oncol.** 2020 Aug 6:S1078-1439(20)30339-2. doi: 10.1016/j.urolonc.2020.07.017.  
PMID: 32773232  
Impact factor: 2.9
72. Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer  
Ilijazi D, Pulverer W, Ertl IE, Lemberger U, Kimura S, **Abufaraj M**, D'Andrea D, Pradere B, Bruchbacher A, Graf A, Soria F, Susani M, Haitel A, Molinaro L, Pycha A, Comploj E, Pabinger S, Weinhäusel A, Egger G, Shariat SF, Hassler MR.  
**Cells** 2020 Aug 5;9(8):E1839. doi: 10.3390/cells9081839.  
PMID: 32764425  
Impact factor: 5.7
73. Associations of moderate to vigorous physical activity and sedentary behavior with depressive and anxiety symptoms in self-isolating people during the COVID-19 pandemic: A cross-sectional survey in Brazil  
Schuch FB, Bulzing RA, Meyer J, Vancampfort D, Firth J, Stubbs B, Grabovac I, Willeit P, Tavares VDO, Calegari VC, Deenik J, López-Sánchez GF, Veronese N, Caperchione CM, Sadarangani KP, **Abufaraj M**, Tully MA, Smith L.  
**Psychiatry Res.** 2020 Jul 27;292:113339. doi: 10.1016/j.psychres.2020.113339.  
PMID: 32745795  
Impact factor: 2.2
74. A Systematic Review and Meta-analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy  
Mori K, **Abufaraj M**, Mostafaei H, Quhal F, Karakiewicz PI, Briganti A, Kimura S, Egawa S, Shariat SF.  
**J Urol.** 2020 Jul 27;101097JU0000000000001305. doi: 10.1097/JU.0000000000001305.  
PMID: 32716694  
Impact factor: 5.9
75. Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent  
Zamboni S, Afferi L, Soria F, Aziz A, **Abufaraj M**, Poyet C, Necchi A, D'Andrea D, Simone G, Ferriero M, Di Trapani E, Simeone C, Antonelli A, Gallina A, Montorsi F, Briganti A, Colombo R, Gandaglia G, Mattei A, Baumeister P, Mordasini L, Hendricksen K, Voskuilen CS, Rink M, Shariat SF, Xylinas E, Moschini M.  
**World J Urol.** 2020 Jul 25. doi: 10.1007/s00345-020-03362-1.  
PMID: 32712850  
Impact factor: 3.2

76. Smoking and bladder cancer: review of the recent literature  
Mori K, Mostafaei H, **Abufaraj M**, Yang L, Egawa S, Shariat SF.  
**Curr Opin Urol** 2020 Jul 20. doi: 10.1097/MOU.0000000000000804.  
PMID: 32701723  
Impact factor: 2.2
77. Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis  
Miura N, Mori K, Mostafaei H, Quhal F, Sari Motlagh R, **Abufaraj M**, Pradere B, Aydh A, Laukhtina E, D'Andrea D, Saika T, Shariat SF.  
**Int J Clin Oncol**. 2020 Jul 17. doi: 10.1007/s10147-020-01747-1.  
PMID: 32681382  
Impact factor: 2.5
78. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.  
**Abufaraj M**, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, Moschini M, Briganti A, Karakiewicz PI, Shariat SF.  
**Eur Urol**. 2020 Jun 27:S0302-2838(20)30429-2. doi: 10.1016/j.eururo.2020.06.002.  
PMID: 32605859  
Impact factor: 17.9
79. The Impact of Cytoreductive Nephrectomy on Survival Outcomes in Patients Treated With Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma in a Real-World Cohort  
Janisch F, Hillemacher T, Fuehner C, D'Andrea D, Meyer CP, Klotzbücher T, Kienapfel C, Vetterlein MW, Kimura S, **Abufaraj M**, Dahlem R, Shariat SF, Fisch M, Rink M.  
**Urol Oncol**. 2020 Jun 21:S1078-1439(20)30192-7. doi: 10.1016/j.urolonc.2020.04.033.  
PMID: 32576526  
Impact factor: 2.9
80. An Overview of Current and Emerging Diagnostic, Staging and Prognostic Markers for Prostate Cancer  
Brönimann S, Pradere B, Karakiewicz P, **Abufaraj M**, Briganti A, Shariat SF.  
**Expert Rev Mol Diagn**. 2020 Jun 18. doi: 10.1080/14737159.2020.1785288.  
PMID: 32552088  
Impact factor: 3
81. Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies  
Soria F, D'Andrea D, **Abufaraj M**, Moschini M, Giordano A, Gust KM, Karakiewicz PI, Babjuk M, Gontero P, Shariat SF.  
**Eur Urol Focus**. 2020 Jun 9:S2405-4569(20)30115-2. doi: 10.1016/j.euf.2020.05.004.

PMID: 32532704

Impact factor: 4.8

82. Ureteric stenting vs not stenting following uncomplicated ureteroscopic lithotripsy: A prospective randomised trial

Al Demour S, Alrabadi A, AlSharif A, Ababneh M, Al-Taher R, Melhem M, Mansi H, Aljamal S, **Abufaraj M**.

**Arab J Urol.** 2020 May 19;18(3):169-175. doi: 10.1080/2090598X.2020.1762280.

PMID: 33029427

Impact factor: ESCI

83. Metastasectomy in Patients With Renal Cell Carcinoma: When and How?

Omid S, **Abufaraj M**, Remzi M.

**Curr Opin Urol** 2020 Jul;30(4):602-609. doi: 10.1097/MOU.0000000000000768.

PMID: 32464043

Impact factor: 2.2

84. The Expression of Urokinase-Type Plasminogen Activator System in Upper Tract Urothelial Carcinoma and Its Prognostic Value After Radical Nephroureterectomy

**Abufaraj M**, Kimura S, Haitel A, Iwata T, Isleem U, D'Andrea D, Soria F, Mori K, Rink M, Bensalah K, Rouprêt M, Margulis V, Briganti A, Karakiewicz PI, Shariat SF.

**Urol Oncol.** 2020 May 4:S1078-1439(20)30136-8. doi: 10.1016/j.urolonc.2020.03.030.

PMID: 32381392

Impact factor: 2.9

85. Regular Coffee Consumption Is Associated With Lower Regional Adiposity Measured by DXA Among US Women

Cao C, Liu Q, **Abufaraj M**, Han Y, Xu T, Waldhoer T, Shariat SF, Li S, Yang L, Smith L.

**J Nutr.** 2020 May 3:nxaa121.doi: 10.1093/jn/nxaa121.

PMID: 32361729

Impact factor: 4.4

86. The Impact of Treatment Modality on Survival in Patients With Clinical Node-Positive Bladder Cancer: Results From a Multicenter Collaboration

Afferi L, Zamboni S, Karnes RJ, Roghmann F, Sargos P, Montorsi F, Briganti A, Gallina A, Mattei A, Schulz GB, Hendricksen K, Voskuilen CS, Rink M, Poyet C, De Cobelli O, di Trapani E, Simeone C, Soligo M, Simone G, Tuderti G, Alvarez-Maestro M, Martínez-Piñeiro L, Aziz A, Shariat SF, **Abufaraj M**, Xylinas E, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group.

**World J Urol.** 2020 Apr 30.doi: 10.1007/s00345-020-03205-z.

PMID: 32356226

Impact factor: 3.2

87. Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?  
Sari Motlagh R, Pradere B, Mori K, Miura N, **Abufaraj M**, Shariat SF.  
**Curr Opin Urol** 2020 Apr 16. doi: 10.1097/MOU.0000000000000769.  
PMID: 32304379  
Impact factor: 2.2
88. The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).  
Janisch F, D'Andrea D, Iwata T, Kimura S, **Abufaraj M**, Enikeev D, Glybochko PV, Karakiewicz PI, Nyirady P, Fajkovic H, Haitel A, Seebacher V, Rink M, Shariat SF.  
**Urol Oncol**. 2020 Mar 21. pii: S1078-1439(20)30043-0. doi: 10.1016/j.urolonc.2020.02.002.  
PMID: 32209281  
Impact factor: 2.9
89. The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical Imaging-Reporting and Data System): A systematic review  
Carando R, Afferi L, Marra G, Krajewski W, Pagliarulo V, **Abufaraj M**, Xylinas E, Cathelineau X, Sanchez-Salas R, Moschini M.  
**Arab J Urol**. 2020 Mar 1;18(2):67-71. doi: 10.1080/2090598X.2020.1733818.  
PMID: 33029409  
Impact factor: ESCI
90. The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nurses' Health Study and Nurses' Health Study II.  
**Abufaraj M**, Shariat S, Moschini M, Rohrer F, Papantoniou K, Devore E, McGrath M, Zhang X, Markt S, Schernhammer E., Briganti A, Ku JH, Muilwijk T, Kassouf W, Matin SF, Spiess PE, Pierorazio PM, Hendricksen K, Shariat SF; UTUC collaboration.  
**Int J Epidemiol**. 2020 Jan 21. pii: dyz264. doi: 10.1093/ije/dyz264.  
PMID: 31965144  
Impact factor: 7.3
91. Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer.  
D'Andrea D, Soria F, Zehetmayer S, Stangl-Kremser J, Grubmüller B, **Abufaraj M**, Gust K, Kimura S, Babjuk M, Goldner GM, Shariat SF  
**Scand J Urol**. 2020 Jan 24:1-6. doi: 10.1080/21681805.2019.1711160.  
PMID: 31975654  
Impact factor: 1.4
92. An update on systemic therapy for penile cancer.  
Resch I, **Abufaraj M**, Hübner NA, Shariat SF.  
**Curr Opin Urol**. 2020 Jan 16. doi: 10.1097/MOU.0000000000000733.

PMID: 30950886

Impact factor: 2.2

93. Efficacy of Preoperative Chemotherapy in High-Risk Upper Tract Urothelial Carcinoma (UTUC).  
Foerster B, **Abufaraj M**, Petros F, Azizi M, Gupta M, Schweitzer D, Margulis V, Iwata T, Kimura S, Shabsigh A, Briganti A, Ku JH, Muilwijk T, Kassouf W, Matin SF, Spiess PE, Pierorazio PM, Hendricksen K, Shariat SF; UTUC collaboration.  
**J Urol.** 2020 Jan 2;101097JU0000000000000737. doi: 10.1097/JU.0000000000000737.  
PMID: 31898919  
Impact factor: 5.9
94. Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis.  
Kimura S, Iwata T, **Abufaraj M**, Janisch F, D'Andrea D, Moschini M, Al-Rawashdeh B, Fajkovic H, Seebacher V, Egawa S, Shariat SF  
**Clin Genitourin Cancer.** 2019 Dec 5. pii: S1558-7673(19)30358-1. doi: 10.1016/j.clgc.2019.11.007.  
PMID: 31889669  
Impact factor: 2.7
95. Second line immune checkpoint inhibition in urothelial cancer.  
Gust KM, **Abufaraj M**, D'Andrea D, Moschini M, Soria F, Shariat SF.  
**Transl Androl Urol.** 2019 Oct;8(5):414-420. doi: 10.21037/tau.2019.09.18.  
PMID: 31807418  
Impact factor: 2.4
96. Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.  
Kimura S, D'Andrea D, Iwata T, Foerster B, Janisch F, Parizi MK, Moschini M, Briganti A, Babjuk M, Chlosta P, Karakiewicz PI, Enikeev D, Rapoport LM, Seebacher V, Egawa S, **Abufaraj M**, Shariat SF.  
**World J Urol.** 2019 Dec 4. doi: 10.1007/s00345-019-03038-5.  
PMID: 31797075  
Impact factor: 3.2
97. Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.  
D'Andrea D, Soria F, **Abufaraj M**, Pones M, Gontero P, Machado AT, Waksman R, Enikeev DV, Glybochko PV, Adonias SP, Nahas WC, Shariat SF, Chade DC.  
**Clin Genitourin Cancer.** 2019 Nov 6. pii: S1558-7673(19)30325-8. doi: 10.1016/j.clgc.2019.10.021.  
PMID: 31786120  
Impact factor: 2.7
98. Overactive bladder symptoms in patients undergoing rigid and flexible cystoscopy.

Saratlija Novakovic Z, Puljak L, Sapunar D, Remzi M, Fajkovic H, Resch I, **Abufaraj M**, Riedl C, Engelhardt P, Hübner W, Breinl E, Duvnjak M, Seklehner S.

**World J Urol.** 2019 Nov 6. doi: 10.1007/s00345-019-02993-3.

PMID: 31691085

Impact factor: 3.2

99. Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis.

Hassler MR, **Abufaraj M**, Kimura S, Stangl-Kremser J, Gust K, Glybochko PV, Schmidinger M, Karakiewicz PI, Shariat SF.

**Clin Genitourin Cancer.** 2019 Sep 27. pii: S1558-7673(19)30273-3. doi: 10.1016/j.clgc.2019.09.004.

PMID: 31668768

Impact factor: 2.7

100. Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer.

Stangl-Kremser J, Lemberger U, Hassler MR, Bruchbacher A, Ilijazi D, Garstka N, Kramer G, Haitel A, **Abufaraj M**, Shariat SF.

**Clin Genitourin Cancer.** 2019 Jun 26. pii: S1558-7673(19)30201-0. doi: 10.1016/j.clgc.2019.06.012.

PMID: 31331867

Impact factor: 2.7

101. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis.

Janisch F, Shariat SF, Baltzer P, Fajkovic H, Kimura S, Iwata T, Korn P, Yang L, Glybochko PV, Rink M, **Abufaraj M**.

**World J Urol.** 2019 Jul 18. doi: 10.1007/s00345-019-02875-8.

PMID: 31321509

Impact factor: 3.2

102. Current Disease Management of Primary Urethral Carcinoma.

Janisch F, **Abufaraj M**, Fajkovic H, Kimura S, Iwata T, Nyirady P, Rink M, Shariat SF.

**Eur Urol Focus.** 2019 Jul 12. pii: S2405-4569(19)30172-5. doi: 10.1016/j.euf.2019.07.001.

PMID: 31307949

Impact factor: 4.8

103. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis.

Kardoust Parizi M, **Abufaraj M**, Fajkovic H, Kimura S, Iwata T, D'Andrea D, Karakiewicz PI, Shariat SF.

**Urol Oncol.** 2019 Jul 8. pii: S1078-1439(19)30236-4. doi: 10.1016/j.urolonc.2019.06.007.

PMID: 31296421

Impact factor: 2.9

104. Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy.
- Abufaraj M**, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M.
- Eur J Nucl Med Mol Imaging.** 2019 Jun 29. doi: 10.1007/s00259-019-04361-0.
- PMID: 31254037
- Impact factor: 7.2
105. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review.
- Iwata T, Kimura S, **Abufaraj M**, Janisch F, Karakiewicz PI, Seebacher V, Rouprêt M, Nasu Y, Shariat SF.
- Urol Oncol.** 2019 Jun 26. pii: S1078-1439(19)30221-2. doi: 10.1016/j.urolonc.2019.05.021.
- PMID: 31255542
- Impact factor: 2.9
106. Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer.
- Iwata T, Kimura S, **Abufaraj M**, Janisch F, Parizi MK, Haitel A, Rink M, Rouprêt M, Fajkovic H, Seebacher V, Nyirady P, Karakiewicz PI, Enikeev D, Rapoport LM, Nasu Y, Shariat SF.
- Urol Oncol.** 2019 Jun 26. pii: S1078-1439(19)30219-4. doi: 10.1016/j.urolonc.2019.05.019.
- PMID: 31255543
- Impact factor: 2.9
107. Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis.
- Kimura S, **Abufaraj M**, Janisch F, Iwata T, Parizi MK, Foerster B, Fossati N, Briganti A, Egawa S, Hartenbach M, Shariat SF.
- Prostate Cancer Prostatic Dis.** 2019 May 30. doi: 10.1038/s41391-019-0156-z.
- PMID: 31147628
- Impact factor: 4.3
108. Comparison of perioperative complications and health-related quality of life between robot-assisted and open radical cystectomy: A systematic review and meta-analysis.
- Kimura S, Iwata T, Foerster B, Fossati N, Briganti A, Nasu Y, Egawa S, **Abufaraj M**, Shariat SF.
- Int J Urol.** 2019 May 13. doi: 10.1111/iju.14005.
- PMID: 31083783
- Impact factor: 2.4
109. Differences in utilization-trend and time changes of peri-operative outcomes of robotic and open radical cystectomy between American and European selected centers: an international multicenter collaboration.

Zamboni S, Soria F, Mathieu R, Xylinas E7, **Abufaraj M**, D'Andrea D, Tan WS, Kelly JD, Simone G, Gallucci M, Meraney A, Krishna S, Konety BR, Antonelli A, Simeone C, Baumeister P, Mattei A, Briganti A, Gallina A, Montorsi F, Rink M, Aziz A, Karakiewicz PI, Rouprêt M, Koupparis A, Scherr DS, Ploussard G, Sooriakumaran P, Shariat SF, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU) Urothelial carcinoma working group; EAU Research Foundation.

**BJU Int.** 2019 May 4. doi: 10.1111/bju.14791

PMID: 31055865

Impact factor: 4.8

110. Association between inflammatory potential of diet and bladder cancer risk:Results from three US prospective cohort studies.

**Abufaraj M**, Tabung FK, Shariat SF, Moschini M, Devore E, Papantoniou K, Yang L, Strohmaier S, Rohrer F, Markt SC, Zhang X, Giovannucci E, Schernhammer E.

**J Urol.** 2019 Apr 22:101097JU0000000000000279. doi: 10.1097/JU.0000000000000279.

PMID: 31009297

Impact factor: 5.9

111. Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization.

D'Andrea D, **Abufaraj M**, Soria F, Gust K, Haitel A, Krakiewicz PI, Shariat SF.

**World J Urol.** 2019 Apr 20. doi: 10.1007/s00345-019-02769-9.

PMID: 31006052

Impact factor: 3.2

112. Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis.

Iwata T, Kimura S, Foerster B, Fossati N, Briganti A, Karakiewicz PI, Gust KM, Egawa S, Nasu Y, **Abufaraj M**, Shariat SF.

**World J Urol.** 2019 Apr 11. doi: 10.1007/s00345-019-02708-8.

PMID: 30976902

Impact factor: 3.2

113. Enhanced Recovery after Radical Cystectomy.

Pozo C, Shariat SF, D'Andrea D, Fajkovic H, **Abufaraj M**.

**Curr Opin Urol.** 2019 May;29(3):227-238. doi: 10.1097/MOU.0000000000000594.

PMID: 30950886

Impact factor: 2.2

114. Incidence and survival outcomes of upper urinary tract urothelial carcinoma (UTUC) patients diagnosed with variant histology treated with nephroureterectomy.

Zamboni S, Foerster B, **Abufaraj M**, Seisen T, Roupret M, Colin P, De la Taille A, Di Bona C, Peyronnet B, Bensalah K, Herout R, Wirth MP, Novotny V, Soria F, Chlosta P, Antonelli A, Simeone C, Baumeister P, Mattei A, Montorsi F, Simone G, Gallucci M, Matsumoto K, Karakiewicz PI,



Briganti A, Xylinas E, Shariat SF, Moschini M; Upper Tract Urothelial Carcinoma Collaboration Group; European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group

**BJU Int.** 2019 Mar 25. doi: 10.1111/bju.14751.

PMID: 30908835

Impact factor: 4.8

115. Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis.

Kardoust Parizi M, Iwata T, Kimura S, Janisch F, **Abufaraj M**, Karakiewicz PI, Enikeev D, Rapoport LM, Hutterer G, Shariat SF.

**Int J Mol Sci.**2019 Mar 19;20(6). pii: E1374. doi: 10.3390/ijms20061374.

PMID: 30893781

Impact factor: 4.1

116. The impact of gender on oncologic outcomes of bladder cancer.

Mun DH, Kimura S, Shariat SF, **Abufaraj M**.

**Curr Opin Urol.** 2019 Mar 6. doi: 10.1097/MOU.0000000000000606.

PMID: 30855378

Impact factor: 2.2

117. Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature.

Foerster B, D'Andrea D, **Abufaraj M**, Broenimann S, Karakiewicz PI, Rouprêt M, Gontero P, Lerner SP, Shariat SF, Soria F.

**Urol Oncol.** 2019 Mar 4. pii: S1078-1439(19)30057-2. doi: 10.1016/j.urolonc.2019.02.004.

PMID: 30846387

Impact factor: 2.9

118. Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis.

Iwata T, Kimura S, Foerster B, **Abufaraj M**, Karakiewicz PI, Preisser F, Nasu Y, Shariat SF.

**Urol Oncol.** 2019 Feb 5. pii: S1078-1439(19)30019-5. doi: 10.1016/j.urolonc.2019.01.018.

PMID: 30737159

Impact factor: 2.9

119. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.

Kimura S, D' Andrea D, Soria F, Foerster B, **Abufaraj M**, Vartolomei MD, Iwata T, Karakiewicz PI, Rink M, Gust KM, Egawa S, Shariat SF.

**Urol Oncol.** 2018 Dec 20. pii: S1078-1439(18)30451-4. doi: 10.1016/j.urolonc.2018.11.005.

PMID: 30580906

Impact factor: 2.9

120. Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder.  
Stangl-Kremser J, D'Andrea D, Vartolomei M, **Abufaraj M**, Goldner G, Baltzer P, Shariat SF, Tamandl D.  
**Urol Oncol.** 2018 Dec 18. pii: S1078-1439(18)30447-2. doi: 10.1016/j.urolonc.2018.11.001.  
PMID: 30578161  
Impact factor: 2.9
121. Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes.  
**Abufaraj M**, Foerster B, Schernhammer E, Moschini M, Kimura S, Hassler MR, Preston MA, Karakiewicz PI, Remzi M, Shariat SF.  
**Eur Urol.** 2018 Dec 12. pii: S0302-2838(18)30956-4. doi: 10.1016/j.eururo.2018.11.052.  
PMID: 30553613  
Impact factor: 17.9
122. Role of serum cholinesterase in patients treated with salvage radical prostatectomy.  
Vartolomei MD, D'Andrea D, Chade DC, Soria F, Kimura S, Foerster B, **Abufaraj M**, Mathieu R, Moschini M, Rouprêt M, Briganti A, Karakiewicz PI, Shariat SF.  
**Urol Oncol.** 2018 Dec 3. pii: S1078-1439(18)30461-7. doi: 10.1016/j.urolonc.2018.11.013.  
PMID: 30522902  
Impact factor: 2.9
123. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study.  
Soria F, Moschini M, D'andrea D, **Abufaraj M**, Foerster B, Mathiéu R, Gust KM, Gontero P, Simone G, Meraney A, Krishna S, Konety B, Rouprêt M, Perry M, Rowe E, Ploussard G, Boorjian SA, Wiklund P, Sooriakumaran P, Shariat SF.  
**Eur Urol Focus.** 2018 Nov 16. pii: S2405-4569(18)30334-1. doi: 10.1016/j.euf.2018.11.002.  
PMID: 30455153  
Impact factor: 4.8
124. Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy.  
D'Andrea D, Soria F, **Abufaraj M**, Gust K, Foerster B, Vartolomei MD, Kimura S, Mari A, Briganti A, Remzi M, Seitz CK, Mathieu R, Karakiewicz PI, Shariat SF.  
**Urol Oncol.** 2018 Nov 13. pii: S1078-1439(18)30356-9. doi: 10.1016/j.urolonc.2018.09.015.  
PMID: 30446461  
Impact factor: 2.9
125. Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma.

Rieken M, Boorjian SA, Kluth LA, Capitanio U, Briganti A, Thompson RH, Leibovich BC, Krabbe LM, Margulis V, Raman JD, Regelman M, Karakiewicz PI, Rouprêt M, **Abufaraj M**, Foerster B, Gönen M, Shariat SF.

**World J Urol.** 2018 Nov 7. doi: 10.1007/s00345-018-2555-5.

PMID: 30406477

Impact factor: 3.2

126. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.

Moschini M, Zaffuto E, Karakiewicz PI, Andrea DD, Foerster B, **Abufaraj M**, Soria F, Mattei A, Montorsi F, Briganti A, Shariat SF

**Eur Urol.** 2018 Oct 4. pii: S0302-2838(18)30722-X. doi: 10.1016/j.eururo.2018.09.034.

PMID: 30293908

Impact factor: 17.9

127. Surgical checklist impact on recurrence-free survival of non-muscle invasive bladder cancer patients undergoing transurethral resection of bladder tumor.

Suarez-Ibarrola R, Soria F, **Abufaraj M**, D'Andrea D, Preto M, Gust KM, Briganti A, Shariat SF, Gontero P.

**BJU Int.** 2018 Sep 24. doi: 10.1111/bju.14557.

PMID: 30248235

Impact factor: 4.8

128. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence.

**Abufaraj M**, Mostafid H, Shariat SF, Babjuk M..

**Curr Opin Urol.** 2018 Aug 21. doi: 10.1097/MOU.0000000000000544.

PMID: 30138122

Impact factor: 2.2

129. Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: A systematic review and meta-analysis.

Kimura S, Mari A, Foerster B, **Abufaraj M**, Vartolomei MD, Stangl-Kremser J, Karakiewicz PI, Egawa S, Shariat SF.

**J Urol.** 2018 Aug 2. pii: S0022-5347(18)43637-3. doi: 10.1016/j.juro.2018.05.162.

PMID: 30077559

Impact factor: 5.9

130. Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.

Kimura S, Soria F, D'Andrea D, Foerster B, **Abufaraj M**, Vartolomei MD, Karakiewicz PI, Mathieu R, Moschini M, Rink M, Egawa S, Shariat SF, Gust KM.

**Clin Genitourin Cancer.** 2018 Jul 6. pii: S1558-7673(18)30415-4. doi: 10.1016/j.clgc.2018.07.002.

PMID: 30061034

Impact factor: 2.7

131. Intermediate and long-term complications associated with adjuvant chemotherapy for stage I germ cell tumor patients.  
 Suarez-Ibarrola R, **Abufaraj M**, Shariat SF.  
**Curr Opin Urol.** 2018 Sep;28(5):485-490. doi: 10.1097/MOU.0000000000000527.  
 PMID: 30044319  
 Impact factor: 2.2
132. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.  
 Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, **Abufaraj M**, Foerster B, Kimura S, Shariat SF.  
**Urol Oncol.** 2018 Jun 5. pii: S1078-1439(18)30166-2. doi: 10.1016/j.urolonc.2018.05.014.  
 PMID: 29884342  
 Impact factor: 2.9
133. A Systematic Review and Meta-Analysis of the impact of Lymphovascular Invasion in Bladder Cancer Transurethral Resection Specimens.  
 Mari A, Kimura S, Foerster B, **Abufaraj M**, D'Andrea D, Hassler M, Minervini A, Rouprêt M, Babjuk M, Shariat SF.  
**BJU Int.** 2018 May 28. doi: 10.1111/bju.14417.  
 PMID: 29807387  
 Impact factor: 4.8
134. Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis.  
 Foerster B, Pozo C, **Abufaraj M**, Mari A, Kimura S, D'Andrea D, John H, Shariat SF.  
**JAMA Oncol.** 2018 May 24. doi: 10.1001/jamaoncol.2018.1071.  
 PMID: 29800115  
 Impact factor: 24.8
135. Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer.  
 D'Andrea D, Hassler MR, **Abufaraj M**, Soria F, Ertl IE, Ilijazi D, Mari A, Foerster B, Egger G, Shariat SF.  
**Expert Rev Anticancer Ther.** 2018 May 8. doi: 10.1080/14737140.2018.1474104.  
 PMID: 29737231  
 Impact factor: 2.6
136. The impact of moderate wine consumption on the risk of developing prostate cancer.  
 Vartolomei MD, Kimura S, Ferro M, Foerster B, **Abufaraj M**, Briganti A, Karakiewicz PI, Shariat SF.  
**Clin Epidemiol.** 2018 Apr 17;10:431-444. doi: 10.2147/CLEP.S163668. eCollection 2018. Review. PMID: 29713200

Impact factor: 3.2

137. A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer.

Mari A, Kimura S, Foerster B, **Abufaraj M**, D'Andrea D, Gust KM, Shariat SF.

**Urol Oncol.** 2018 Apr 20. pii: S1078-1439(18)30114-5. doi: 10.1016/j.urolonc.2018.03.018. Review. PMID: 29685374

Impact factor: 2.9

138. Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence.

Rieken M, Kluth LA, Fajkovic H, Capitanio U, Briganti A, Krabbe LM, Margulis V, **Abufaraj M**, Mari A, Foerster B, Raman JD, Regelman M, Brookman-May S, Sjoberg DD, Karakiewicz PI, Shariat SF.

**Clin Genitourin Cancer.** 2018 Mar 24. pii: S1558-7673(18)30212-X. doi: 10.1016/j.clgc.2018.03.003. PMID: 29653814

Impact factor: 2.7

139. Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer.

Ilijazi D, **Abufaraj M**, Hassler MR, Ertl IE, D'Andrea D, Shariat SF.

**Expert Rev Mol Diagn.** 2018 Mar 21:1-10. doi: 10.1080/14737159.2018.1453808.

PMID: 29542328

Impact factor: 3

140. Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool.

D Andrea D, **Abufaraj M\***, Susani M, Ristl R, Foerster B, Kimura S, Mari A, Soria F, Briganti A, Karakiewicz PI, Gust KM, Rouprêt M, Shariat SF.

**Urol Oncol.** 2018 Mar 2. pii: S1078-1439(18)30040-1. doi: 10.1016/j.urolonc.2018.01.018 PMID: 29506941

Impact factor: 2.9

141. Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients.

Vartolomei MD, Kimura S, Ferro M, Vartolomei L, Foerster B, **Abufaraj M**, Shariat SF.

**World J Urol.** 2018 Feb 21. doi: 10.1007/s00345-018-2235-5. Review.

PMID: 29468284

Impact factor: 3.2

142. Sling Surgery for Female Incontinence.

Sievert KD, **Abufaraj M**, Kernig k, Dräger DL, Blaganje M, Hakenberg O, Mansy K, Liedl B, Tarcan T, de Ridder D

**Eur Urol Suppl.** 2018 Feb 1. doi.org/10.1016/j.eursup.2017.12.003.

Impact factor: 3.1

143. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.  
Özsoy M, D'Andrea D, Moschini M, Foerster B, **Abufaraj M**, Mathieu R, Briganti A, Karakiewicz PI, Roupret M, Seitz C, Czech AK, Susani M, Shariat SF.  
**Urol Oncol.** 2017 Dec 26. pii: S1078-1439(17)30613-0. doi: 10.1016/j.urolonc.2017.12.003.  
PMID: 29288003  
Impact factor: 2.9
144. Robot-assisted partial nephrectomy: systematic review of functional results.  
Foerster B, Kimura S, Vartolomei MD, **Abufaraj M**, Gust K, Fajkovic H, Shariat SF, Seitz C.  
**Curr Opin Urol.** 2017 Dec 22. doi: 10.1097/MOU.0000000000000482.  
PMID: 29278584  
Impact factor: 2.2
145. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature.  
Mari A, Campi R, Tellini R, Gandaglia G, Albisinni S, **Abufaraj M**, Hatzichristodoulou G, Montorsi F, van Velthoven R, Carini M, Minervini A, Shariat SF.  
**World J Urol.** 2017 Nov 16. doi: 10.1007/s00345-017-2115-4.  
PMID: 29147759  
Impact factor: 3.2
146. Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder.  
**Abufaraj M**, Shariat SF, Foerster B, Pozo C, Moschini M, D'Andrea D, Mathieu R, Susani M, Czech AK, Karakiewicz PI, Seebacher V.  
**World J Urol.** 2017 Nov 11. doi: 10.1007/s00345-017-2116-3.  
PMID: 29127452  
Impact factor: 3.2
147. The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.  
**Abufaraj M**, Dalbagni G, Daneshmand S, Horenblas S, Kamat AM, Kanzaki R, Zlotta AR, Shariat SF.  
**Eur Urol.** 2017 Nov 6. pii: S0302-2838(17)30840-0. doi: 10.1016/j.eururo.2017.09.030.  
PMID: 29122377  
Impact factor: 17.9
148. Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer.  
Mari A, **Abufaraj M**, Foerster B, Özsoy M, Briganti A, Rouprêt M, Karakiewicz PI, Mathieu R, D'Andrea D, Chade DC, Shariat SF.  
**Clin Genitourin Cancer.** 2017 Nov 10. pii: S1558-7673(17)30331-2. doi: 10.1016/j.clgc.2017.10.015.  
PMID: 29239845

Impact factor: 2.7

149. Novel endoscopic visualization techniques for bladder cancer detection: a review of the contemporary literature.

Mari A, **Abufaraj M\***, Gust KM, Shariat SF.

**Curr Opin Urol.** 2017 Oct 17. doi: 10.1097/MOU.0000000000000459.

PMID: 29045251

Impact factor: 2.2

150. Genetic determinants for chemo-and radiotherapy resistance in bladder cancer.

Mari A, D'Andrea D, **Abufaraj M**, Foerster B, Kimura S, Shariat SF.

**Transl Androl Urol.** 2017 Aug 9. doi: 10.21037/tau.2017.08.19

PMID: 29354495

Impact factor: 2.1

151. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer.

Rieken M, Shariat SF, Kluth L, Crivelli JJ, **Abufaraj M**, Foerster B, Mari A, Ilijazi D, Karakiewicz PI, Babjuk M, Gönen M, Xylinas E.

**Urol Oncol.** 2017 Sep 22. pii: S1078-1439(17)30461-1. doi: 10.1016/j.urolonc.2017.08.027.

PMID: 28947304

Impact factor: 2.9

152. Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study.

Malte R, Kluth LA, Kaushik D, Boorjian SA, **Abufaraj M**, Foerster B, Rink M, Gust K, Roghmann F, Noldus J, Vordos D, Hagiwara M, Kikuchi E, Ikeda M, Matsumoto K, Karakiewicz PI, Rouprêt M, Briganti A, Scherr DS, Shariat SF, Seebacher V.

**Eur J Surg Oncol.** 2017 Sep 7. pii: S0748-7983(17)30652-2. doi: 10.1016/j.ejso.2017.08.013.

PMID: 28928012

Impact factor: 3.7

153. External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Population-based Study.

Rieken M, Kluth LA, Seitz C, **Abufaraj M**, Foerster B, Mathieu R, Karakiewicz PI, Bachmann A, Briganti A, Rouprêt M, Gönen M, Shariat SF, Seebacher V.

**Clin Genitourin Cancer.** 2017 Aug 24. pii: S1558-7673(17)30243-4. doi: 10.1016/j.clgc.2017.08.002.

PMID: 28916272

Impact factor: 2.7

154. Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy.

Moschini M, Shariat SF, **Abufaraj M**, Foerster B, D Andrea D, Soria F, Dell'Oglio P, Mattei A, Montorsi F, Colombo R, Briganti A, Gallina A.

- Urol Oncol.** 2017 Sep 5. pii: S1078-1439(17)30423-4. doi: 10.1016/j.urolonc.2017.08.013.  
PMID: 28887096  
Impact factor: 2.9
155. Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer.  
**Abufaraj M**, Haitel A, Moschini M, Gust K, Foerster B, Özsoy M, D'Andrea D, Karakiewicz PI, Rouprêt M, Briganti A, Shariat SF.  
**Clin Genitourin Cancer.** 2017 Aug 15. pii: S1558-7673(17)30198-2. doi: 10.1016/j.clgc.2017.07.001.  
PMID: 28851591  
Impact factor: 2.7
156. Frequency and prognostic value of PTEN loss in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.  
Rieken M, Shariat SF, Karam JA, Foerster B, Khani F, Gust K, **Abufaraj M**, Wood CG, Weizer AZ, Raman JD, Guo CC, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Bachmann A, De Marzo AM, Robinson BD, Margulis V.  
**J Urol.** 2017 Jul 11. pii: S0022-5347(17)77101-7. doi: 10.1016/j.juro.2017.06.096.  
PMID: 28709887  
Impact factor: 5.9
157. Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma.  
Foerster B, Moschini M, **Abufaraj M**, Soria F, Gust KM, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Kluth L, Mathieu R, Margulis V, Lotan Y, Aziz A, John H, Shariat SF; UTUC Collaboration.  
**Clin Genitourin Cancer.** 2017 Jun 19. pii: S1558-7673(17)30169-6. doi: 10.1016/j.clgc.2017.06.003.  
PMID: 28694147  
Impact factor: 2.7
158. Caveolin-1 Expression in Upper Tract Urothelial Carcinoma.  
D'Andrea D, Moschini M, Foerster B, **Abufaraj M**, Margulis V, Karam J, Lotan Y, Raman J, Mathieu R, Rouprêt M, Karakiewicz PI, Briganti A, Haitel A, Shariat SF.  
**Eur Urol Focus.** 2017 Jul 1. pii: S2405-4569(17)30162-1. doi: 10.1016/j.euf.2017.06.011.  
PMID: 28753840  
Impact factor: 4.8
159. Obesity and its implications on nononcological urological surgery.  
Mari A, **Abufaraj M\***, Mansy K, Sievert KD.  
**Curr Opin Urol.** 2017 Jun 24. doi: 10.1097/MOU.0000000000000430.  
PMID: 28650868  
Impact factor: 2.2



160. Obesity and its implications on oncological urological surgery.  
**Abufaraj M**, Mari A, Mansy K, Sievert KD.  
**Curr Opin Urol.** 2017 Jun 24. doi: 10.1097/MOU.0000000000000429.  
 PMID: 28650867  
 Impact factor: 2.2
161. Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients.  
 Soria F, Moschini M, Wirth GJ, Gust KM, Klatte T, Briganti A, Gontero P, **Abufaraj M**, Özsoy M, Karakiewicz PI, Shariat SF.  
**Urology.** 2017 May 12. pii: S0090-4295(17)30487-9. doi: 10.1016/j.urology.2017.04.049.  
 PMID: 28506860  
 Impact factor: 1.9
162. Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study.  
 Maj-Hes AB, Mathieu R, Özsoy M, Soria F, Moschini M, **Abufaraj M**, Briganti A, Roupret M, Karakiewicz PI, Klatte T, Shariat SF.  
**Urol Oncol.** 2017 Jul;35(7):460.e1-460.e8. doi: 10.1016/j.urolonc.2017.01.022. Epub 2017 Apr 29.  
 PMID: 28460801  
 Impact factor: 2.9
163. Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study.  
 Moschini M, Shariat SF, Freschi M, Soria F, D'Andrea D, **Abufaraj M**, Foerster B, Dell'Oglio P, Zaffuto E, Mattei A, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R.  
**Urol Oncol.** 2017 Apr 19. pii: S1078-1439(17)30133-3. doi: 10.1016/j.urolonc.2017.03.024.  
 PMID: 28433471  
 Impact factor: 2.9
164. Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer.  
 Soria F, Lucca I, Moschini M, Mathieu R, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Gust KM, Hassler MR, Foerster B, **Abufarraj M**, Haitel A, Klatte T, Shariat SF.  
**Urol Oncol.** 2017 Jun;35(6):356-362. doi: 10.1016/j.urolonc.2017.02.009. Epub 2017 Mar 23.  
 PMID: 28342660  
 Impact factor: 2.9
165. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer.  
 D'Andrea D, Moschini M, Gust K, **Abufaraj M**, Özsoy M, Mathieu R, Soria F, Briganti A, Rouprêt M, Karakiewicz PI, Shariat SF.

- Clin Genitourin Cancer.** 2017 Mar 27. pii: S1558-7673(17)30069-1. doi: 10.1016/j.clgc.2017.03.007.  
PMID: 28420564  
Impact factor: 2.7
166. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy.  
Moschini M, Foerster B, **Abufaraj M**, Soria F, Seisen T, Roupret M, Colin P, De la Taille A, Peyronnet B, Bensalah K, Herout R, Wirth MP, Novotny V, Chlosta P, Bandini M, Montorsi F, Simone G, Gallucci M, Romeo G, Matsumoto K, Karakiewicz P, Briganti A, Shariat SF.  
**World J Urol.** 2017 Feb 28. doi: 10.1007/s00345-017-2026-4.  
PMID: 28247066  
Impact factor: 3.2
167. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.  
**Abufaraj M**, Shariat SF, Haitel A, Moschini M, Foerster B, Chlosta P, Gust K, Babjuk M, Briganti A, Karakiewicz PI, Albrecht W.  
**Urol Oncol.** 2017 May;35(5):264-271. doi: 10.1016/j.urolonc.2017.01.012. Epub 2017 Feb 14.  
PMID: 28214283  
Impact factor: 2.9
168. Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy.  
Moschini M, Soria F, **Abufaraj M**, Foerster B, D'Andrea D, Damiano R, Klatte T, Montorsi F, Briganti A, Colombo R, Gallina A, Shariat SF.  
**Clin Genitourin Cancer.** 2017 Jan 11. pii: S1558-7673(17)30001-0. doi: 10.1016/j.clgc.2017.01.001.  
PMID: 28162943  
Impact factor: 2.7
169. Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer.  
Moschini M, Shariat SF, Freschi M, Soria F, **Abufaraj M**, Gandaglia G, Dell'Oglio P, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R.  
**Urol Int.** 2017;98(3):290-297. doi: 10.1159/000454736. Epub 2017 Feb 1.  
PMID: 28142141  
Impact factor: 1.4
170. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy.  
D'Andrea D, Moschini M, Gust KM, **Abufaraj M**, Özsoy M, Mathieu R, Soria F, Briganti A, Rouprêt M, Karakiewicz PI, Shariat SF.  
**J Surg Oncol.** 2017 Mar;115(4):455-461. doi: 10.1002/jso.24521. Epub 2017 Jan 20.  
PMID: 28105663  
Impact factor: 3.1

171. Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients.  
 Moschini M, Shariat SF, Lucianò R, D'Andrea D, Foerster B, **Abufaraj M**, Bandini M, Dell'Oglio P, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A.  
**Clin Genitourin Cancer.** 2016 Dec 14. pii: S1558-7673(16)30352-4. doi: 10.1016/j.clgc.2016.12.006.  
 PMID: 28040422  
 Impact factor: 2.7
172. The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes.  
 Moschini M, Shariat SF, **Abufaraj M**, Soria F, Klatte T, Croce G, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A.  
**Urol Oncol.** 2017 Apr;35(4):151.e17-151.e23. doi: 10.1016/j.urolonc.2016.11.003. Epub 2016 Dec 5.  
 PMID: 27932269  
 Impact factor: 2.9
173. Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer.  
 Soria F, Moschini M, **Abufaraj M**, Wirth GJ, Foerster B, Gust KM, Özsoy M, Briganti A, Gontero P, Mathieu R, Rouprêt M, Karakiewicz PI, Shariat SF.  
**Urol Oncol.** 2017 Mar;35(3):113.e9-113.e14. doi: 10.1016/j.urolonc.2016.10.021. Epub 2016 Nov 28. PMID: 27908681  
 Impact factor: 2.9
174. Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study.  
**Abufaraj M**, Moschini M, Soria F, Gust K, Özsoy M, Mathieu R, Rouprêt M, Margulis V, Karam JA, Wood CG, Briganti A, Bensalah K, Haitel A, Shariat SF.  
**World J Urol.** 2017 Jul;35(7):1073-1080. doi: 10.1007/s00345-016-1968-2. Epub 2016 Nov 9.  
 PMID: 27830374  
 Impact factor: 3.2
175. Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery.  
**Abufaraj M**, Gust K, Moschini M, Foerster B, Soria F, Mathieu R, Shariat SF.  
**Transl Androl Urol.** 2016 Oct;5(5):735-744. Review.  
 PMID: 27785430  
 Impact factor: 2.1
- Impact factor reported according to the 2020 Web of Science Journal Citation Reports (JCR)

## PROFESSIONAL ACTIVITY

---

- Reviewer for The Lancet Oncology

- Reviewer for Nature Reviews Clinical Oncology
- Reviewer for European Urology
- Reviewer for Prostate Cancer and Prostatic Diseases
- Reviewer for The Journal of Urology
- Reviewer for BJU International
- Reviewer for European Urology Focus
- Reviewer for Urologic Oncology: Seminars and original investigations
- Reviewer for Cancer Medicine
- Reviewer for Cancer Causes and Control
- Reviewer for Clinical Genitourinary Cancer
- Reviewer for World Journal of Urology
- Reviewer for Cancer Epidemiology
- Reviewer for International Journal for Urology
- Reviewer for Journal of Clinical Medicine
- Reviewer for Expert Review of Molecular Diagnostics
- Reviewer for Scandinavian Journal of Urology
- Reviewer for The Arab Journal of Urology
- Reviewer for International Brazilian Journal Of Urology
- Reviewer for Turkish Journal of Urology
- Reviewer for Frontiers in Surgery
- Reviewer for Frontiers in Oncology
- Reviewer for Frontiers in Medicine
- Reviewer for Bladder Cancer Journal
- Reviewer for Clinics in Surgery

Publons identifier: [publons.com/a/1270633/](https://publons.com/a/1270633/)

- Reviewer for Surgery in Motion section in the European Urology which deals with manuscripts describing particular new surgical techniques.
- Reviewer for the Undergraduate Project Funding Program provided by King Abdullah II Fund for Development in partnership with the King Abdullah II Development and Design Bureau.
- Reviewer for the World Congress of Endourology yearly meeting assisting in the process of evaluating the abstract presented to the conference.
- Reviewer for the 9th Emirates International Urological Conference and 17th Annual Arab Association of Urology Conference meeting assisting in the process of evaluating the abstract presented to the conference, 2020.
- Co-authored a report for the Center for Strategic Studies/ the University of Jordan about the current situation and recommendations for the post COVID-19 era in Jordan. The report was published in Arabic Language and aimed at providing government bodies and organizations in the

public and private sectors with recommendation about the post COVID-19 era with emphasis on health care system and challenges facing it. April 2020

- Co-authored: Viewpoint: Jordan's Public and Surveillance Health Policies: During and After COVID-19 at the Jordan Journal of Pharmaceutical Sciences. The article proposed interventions that inform activities in seven priority health system areas to manage during and after the pandemic. Raeda Al Qutob, Musa Taha Ajlouni, **Mohammad Abufaraj**, Immanuel Azaad Moonesar R.D
- Section Editor at Current Opinion in Urology. Special issue titled: Health care factors in Urology, Volume 31 Issue 4. Shahrokh F. Shariat and **Mohammad Abufaraj**. July 2021

## **SELECTED PRESENTATIONS AND ACTIVITIES IN INTERNATIONAL CONFERENCES & MEETINGS**

---

- **Abufaraj M**, The role of early radical cystectomy in patients with non muscle invasive bladder cancer , Presented at Africa Health ExCon Exhibition Conferences 5th to June 7th, 2022, Cairo, Egypt
- **Abufaraj M**, Trimodal Therapy In Muscle Invasive Bladder Cancer , Presented at the 18th Arab Association of Urology Annual conference in collaboration with the 55th Annual congress of Egyptian Urological Association meeting, December 2021, Hurghada, Egypt
- **Abufaraj M**, An Update on The Management of Small Renal Masses , presented at the Excellence in Oncology Care 2021 meeting, October 2021, Dubai, United Arab Emirates
- **Abufaraj M**, Neoadjuvant chemotherapy in upper urothelial cancer , presented at the European Association of Urology (EAU 21) virtual meeting. Urology beyond Europe. Session: Joint Session of the European Association of Urology (EAU) and the Arab Association of Urology (AAU)
- **Abufaraj M**, Gender-based differential Impact of COVID-19 Crisis on Health Indices: A Nationwide Cross-sectional Study. Presenting the results of a nationwide cross sectional study that was supported by the UN Women-Jordan under its Flagship Program Initiative Making Every Woman and Girl Count. This virtual meeting was conducted by the Economic and Social Council and attended by the Health Committee members at the house of representative and senate, and officials from the Ministry of Health. 28th January, 2021, Amman, Jordan.
- **Abufaraj M**, An Overactive Bladder Patient Treated with Mirabegron: A Case Presentation. Presented at Astellas uroacademy, January, 2020, Amman, Jordan.
- **Abufaraj M**, Image Enhancement Technologies in the Detection of Upper Tract Urothelial Carcinoma. Presented at The 37th World Congress of Endourology, October, 2019, Abu Dhabi, United Arab Emirates.
- **Abufaraj M**, The role of radical cystectomy in non muscle invasive bladder cancer. Presented at the 11th international conference of the Jordanian Association of Urological Surgeons, October, 2019, Amman, Jordan.
- **Abufaraj M**, Instructor in a two-day workshop about study design and medical writing 11th international conference of the Jordanian Association of Urological Surgeons, October, 2019, Amman, Jordan.
- **Abufaraj M**, Trimodal therapy in muscle-invasive bladder cancer , presented at the Main Auditorium/ SIU joint Session in the 16th Annual Arab Association of Urology Conference, June, 2019, Casablanca, Morocco.
- **Abufaraj M**, Upper Tract Urothelial Carcinoma: The role of perioperative chemotherapy , presented at the Main Auditorium of 16th Annual Arab Association of Urology Conference, June, 2019, Casablanca, Morocco.

- **Abufaraj M**, Early radical cystectomy in non-muscle invasive bladder cancer , presented in a uro-oncology course held at the 16th Annual Arab Association of Urology Conference in collaboration with Arab School of Urology, June, 2019, Casablanca, Morocco.
- **Abufaraj M**, Moderator in a one-day workshop about medical writing, study design and statistics in Urology in the 15th Annual Arab Association of Urology Conference. June, 2019, Casablanca, Morocco.
- **Abufaraj M**, How do these trials change my daily practice? The STAMPEDE trial , presented at Controversies in Urologic Oncology, March, 2019, Vienna, Austria.
- **Abufaraj M**, Overview on recent bladder cancer research , presented at Amsterdam Medical Center bladder cancer meeting, March, 2019, Amsterdam, Netherlands.
- **Abufaraj M**, The impact of hormones and reproductive factors on the risk of bladder cancer in women: Results from nurses' health study and nurses' health study II , presented at the European Association of Urology (EAU 19) meeting, March, 2019, Barcelona, Spain.
- **Abufaraj M**, Prevalence and trends in kidney stone among adults in the United States, 2007-2014 , presented at the European Association of Urology (EAU 19) meeting, March, 2019, Barcelona, Spain.
- **Abufaraj M**, Robotic-assisted vs open radical prostatectomy: contemporary data , an update lecture presented at the Onkologisch-Laparoskopischen und Roboterchirurgischen Herbstsymposiums, November, 2018, Krems, Austria.
- **Abufaraj M**, Moderator in a one-day workshop about medical writing and study design in the 7th Emirates International Urological Conference and 15th Annual Arab Association of Urology Conference. November, 2018 Dubai, United Arab Emirates.
- **Abufaraj M**, The role of biomarkers in bladder cancer , a plenary session lecture presented at the XXVII congress of the Italian Society of Urologic Oncology (SIUrO), April, 2018, Milan, Italy.
- **Abufaraj M**, Prospective evaluation of the performance of 68Ga-PSMA 11-PET CT/MRI imaging for lymph node staging in patients with biochemical recurrence after radical prostatectomy , presented at the European Association of Urology (EAU 18) meeting , March, 2018, Copenhagen Denmark.
- **Abufaraj M**, Association between inflammatory potential in diet and bladder cancer risk: Results from three US prospective cohort studies , presented at the European Association of Urology (EAU 18) meeting , March, 2018, Copenhagen Denmark.
- **Abufaraj M**, Value of repeated ureterorenoscopy within the first 3 months after endoscopic treatment in upper tract urothelial carcinoma (UTUC) , presented at the European Association of Urology (EAU 19) meeting , March, 2018, Copenhagen Denmark.
- **Abufaraj M**, Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool , presented at the European Association of Urology (EAU 19) meeting , March, 2018, Copenhagen Denmark.
- **Abufaraj M**, Accuracy and Prognostic Value of Variant Histology and Lymphovascular Invasion at Transurethral Resection of Bladder , presented at the Société Internationale d'Urologie (SIU) meeting , October, 2017, Lisbon, Portugal.
- **Abufaraj M**, Characterization of late recurrence after radical cystectomy in a large multicenter cohort of bladder cancer patients , presented at the Central European Meeting (CEM 16) meeting, October, 2016, Vienna, Austria.

- **Abufaraj M**, Preoperative anemia is a predictor of disease recurrence, cancer-specific survival and overall survival in bladder cancer patients: A retrospective study on 4335 radical cystectomies , presented at the Central European Meeting (CEM 16) meeting, October, 2016, Vienna, Austria.
- **Abufaraj M**, Prognostic value of the 2015 ISUP Gleason grading system: A multiinstitutional validation study , presented at the Central European Meeting (CEM 16) meeting, October, 2016, Vienna, Austria.
- **Abufaraj M**, The impact of HER2 status on oncological outcomes of patients with invasive bladder cancer , presented at the Central European Meeting (CEM 16) meeting, October, 2016, Vienna, Austria.
- **Abufaraj M**, Urinary Diversions and Orthotopic bladder KAUIH experience , presented at the 8th International conference of the Jordanian Association of Urological Surgeons, October, 2013, Amman-Jordan.

## HONORS AND AWARDS

---

- Distinguished Researcher Award at the University of Jordan. The University of Jordan grants this yearly award to recognize the contribution of an individual whose scientific research output has significantly contributed to the progress of the rank of the University of Jordan based on the total number of publications and citations. *2020*
- Co-author of the Best poster and awarded the first Berlin Chemie for the Presentation entitled: A systematic review on the management of primary urethral carcinoma at the EAU 19th Central European Meeting in conjunction with the Austrian Society of Urology and the Bavarian Society of Urology, Vienna. *May 2019*
- Best researcher award at the department of Urology, Medical University of Vienna. This award is granted based on the impact points achieved during the last academic year. *2018*
- Awarded the European Urological Scholarship Program grant ( **EUUSP/Scholarship S-01-2018**). *2018*
- Co-author of the Best poster in session "Cystectomy - histology, lymph nodes and prognostics..." with the abstract entitled "Prognostic value of concomitant carcinoma in situ in radical cystectomy specimens on patients with bladder cancer: A meta-analysis of 24,136 patients" at the time of the 33rd Annual EAU Congress Copenhagen, Denmark. *2018*
- Best researcher award at the department of Urology, Medical University of Vienna. This award is granted based on the impact points achieved during the last academic year. *2017*
- Awarded a certificate of outstanding contribution in reviewing for Urologic Oncology: Seminars and Original Investigations as a recognition for being within the top 10th percentile of reviewers for the Journal *2017*
- Graduated with honorary degree from medical school.
- Full academic scholarship from the Ministry of Higher Education to attend Medical School at Jordan University of Science and Technology. *2003-2009*
- General Secondary Certificate (Scientific Branch), 98.9 percentile.

## PROFESSIONAL AFFILIATION

---

- Member of European association of urology
- Member of The society of international urology/ Société Internationale d'Urologie
- Member of Jordan Medical Council

- Member of European Uro-Oncology Group (EUOG)
- Member of Jordan Medical Association
- Member of the Arab Association of Urology
- Member of the Arab School of Urology
- Member of Jordanian Association of Urological Surgeons
- Member of Jordan Pain Association

## **TEACHING EXPERIENCE**

---

- Examiner in the Arab Board of Urology at The Jordan University of Science and Technology, Irbid, Jordan (April 2021).
- Participated in creating and launching the Arab Association of Urology Smart Learning Group in collaboration with the Arab School of Urology. This platform aims to enhance the urological knowledge and professional skills among doctors at any stage of a urological career, and for allied professionals working in the area using a wide range of materials and techniques (April, 2020).
- Examiner in the Arab Board of Urology at The Jordan University of Science and Technology, Irbid, Jordan (Feb 2020).
- Examiner in the End of Service Exam for Urology residents' at The Jordan University Hospital, The University of Jordan.
- Examiner in the Objective Structured Clinical Examination (OSCE) examinations for the fourth, fifth and sixth year medical students' at The University of Jordan.
- Participated actively in the research activity in the Department of Urology at the Medical university of Vienna. These activities included a weekly research meeting with resident, fellows and lab workers. These meetings were the group-oriented discussions where participants suggested compelling research questions and follow-up the ongoing projects. Toward the end of the fellowship training, my duties included leading these research meeting and mentoring residents and junior fellows.
- Participated in teaching 3rd year medical students at the Jordan University of Science and Technology via Clinical Case discussion in the Genitourinary system module.
- Participated in teaching 4th and 6th year medical student via clinical rounds, seminars , lectures and basic surgical training at King Abdullah University Hospital, Jordan University of Science and Technology.
- Participated in the Objective Structured Clinical Examination (OSCE) committee for fourth and fifth year medical students' at the Jordan University of Science and Technology .
- Participated in orientation courses for new urology residents and interns at King Abdullah University Hospital .

## **MEDIA INTERVIEWS AND ARTICLES FOR PRESS RELEASE**

---

- Reuters, June 6, 2018: "Prostate cancer survival odds worse for smokers" based on JAMA Oncology publication titled: "Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis" (PMID: 29800115).
- Press release from the EAU 19 Congress, Barcelona 2019: "Early menopause in smokers linked to bladder cancer" and "Age at Menopause May Play a Role in Bladder Cancer Risk". More than



40 newspapers and health care related websites reported the results of our analysis titled "The impact of hormones and reproductive factors on the risk of bladder cancer in women: Results from Nurses' Health Study and Nurses' Health Study II". This work was presented at the congress and selected for press release.

- A Newspaper article and an interview in the Der Standard which is an Austrian daily newspaper published in Vienna, Austria: Vorzeitige Menopause erhöht bei Raucherinnen Blasenkrebsrisiko.
- Efficacy of Preoperative Chemotherapy in High-Risk Upper Tract Urothelial Carcinoma. [www.renalandurologynews.com](http://www.renalandurologynews.com)
- The Jordan Times, March 21, 2020: "UJ study on Jordan situation forecasts positive outcome from early COVID-19 measures" based on an editorial about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Jordan titled: COVID-19: Where does Jordan stand?". The Jordan Times is an English-language daily newspaper published by the Jordan Press Foundation.
- Al Ra'i Newspaper, March 26, 2020, and Alghad Newspaper, March 27, 2020: "The impact of self-isolation on the mental health among Jordanian: The COVID-19 crisis" preliminary results of cross sectional conducted during the COVID-19 self-isolation measures and curfew. These results are published in several news websites and official newspapers.
- The Jordan Times, April 1st, 2020: "Jordan's efforts to contain COVID-19: A careful interpretation of the encouraging numbers". An article written for the Jordan Times, an English-language daily newspaper published by the Jordan Press Foundation.
- The Jordan Times, April 8th, 2020: "The 3 T's model: Hitting the nail on the head". An article written for the Jordan Times, an English-language daily newspaper published by the Jordan Press Foundation.

## **ADMINISTRATIVE EXPERIENCE**

---

- Member of the Institutional Review Board (IRB) at the University of Jordan The IRB is the administrative body established to protect the rights and welfare of human research subjects recruited to participate in research activities at the University of Jordanl. *November 2021-now*
- Member of the Institutional Review Board (IRB) at the Jordan University Hospital. The Jordan University Hospital IRB is the administrative body established to protect the rights and welfare of human research subjects recruited to participate in research activities at the Jordan University Hospital. *September 2021-now*
- Member of the Young Academic Urologists (YAU)-Urothelial Cancer working party. The Young Academic Urologists (YAU) is an expert group of talented and already renowned European young urologists with the purpose of boosting research activity in some critical areas of urology and improving academic collaboration among different centres in Europe. The expert groups aim at scientific cooperation, study design or other scientific output. *January 2021-now*
- Head of a committee to prepare the Executive Program Plan of the University of Jordan Hospital 2021-2025. The committee's main aim was to prepare a detailed plan for the top-priority projects, needs, and expectations in the next five years at the University of Jordan Hospital. This plan was submitted to the Ministry of Planning and International Cooperation as a part of national effort to put forward a national comprehensive policy and executive plan for the health sector. *November 2020*
- Member of the Uro-Oncology committee in the Arab School of Urology. This committee focuses primarily on providing education and training to young urologists in the field of uro-oncology. *October 2019*

- Member of the Research Committee at the Faculty of Medicine, the University of Jordan  
*September 2019-September 2020*
- Member of the Evidence Based Committee at the Jordan University Hospital, the University of Jordan  
*September 2019*
- Co-Editors-in-Chief of the Arab Journal of Urology  
*July 2019*

The Arab Journal of Urology (known as Arab J Urol) is a peer-reviewed journal published by Taylor and Francis that strives to provide a high standard of research and clinical material to the widest possible urological community worldwide. The journal encompasses all aspects of urology including: urological oncology, urological reconstructive surgery, urodynamics, female urology, pediatric urology, endourology, transplantation, erectile dysfunction, and urinary infections and inflammations. The journal provides reviews, original articles, editorials, surgical techniques, cases reports and correspondence.

- Member of Quality Assurance and Development Affairs Committee in the Faculty of Medicine, the University of Jordan  
*July 2019*
- Social Medial Editor at the Current Opinion of Urology, a 1.7-impact factor review journal published bimonthly by Elsevier  
*December 2018*

Current Opinion in Urology delivers a broad-based perspective on the most recent and most exciting developments in urology from across the world. Published bimonthly and featuring ten key topics – including focuses on prostate cancer, bladder cancer and minimally invasive urology – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.

- Member of the Research council of the Arab School of Urology. The main task of the research council is to support Arab researches in conducting their academic activities at a standard level, and to support urological multi-center studies/registries across the Arab world. The committee is organizing medical writing courses at national and international meetings for medical students, interns, urology residents and young urologists.  
*October 2018*
- Head administrator during the final two years of residency during calls, on average once or twice per month. Responsibilities comprise of maintaining the smooth running of medical services at the hospital during out-of-hours to achieve effective clinical care .
- Member of Patients Records Audit Committee, King Abdullah University Hospital  
*December 2014*

---

## COMPUTER SKILLS

- Operating Systems: MS Windows, and Mac OS.
- MS Office, L<sup>A</sup>T<sub>E</sub>X.

---

## AUXILIARY INFORMATION

- Arabic (Mother tongue)
- English
- German

---

## REFERENCES

- Prof. Shahrokh F. Shariat  
Professor and Chairman  
Department of Urology  
Comprehensive Cancer Center  
Medical University Vienna  
Vienna General Hospital  
Tel: 43 1 4040026150  
Fax: 43 1 40400 23320  
Email: shahrokh.shariat@meduniwien.ac.at
- Prof. Eva Schernhammer  
Department of Epidemiology  
Channing Division of Network Medicine  
Department of Medicine, Harvard Medical School  
Boston, Massachusetts 02115  
Phone: 617.525.4648  
Email: nhess@channing.harvard.edu
- Prof. Christian Seitz  
Vice Chairman  
Department of Urology  
Medical University Vienna  
Vienna General Hospital  
Tel: 43 1 4040026150  
Fax: 43 1 40400 23320  
Email: christian.seitz@meduniwien.ac.at@meduniwien.ac.at
- Prof. Ibrahim H. Bani-Hani  
Professor of Urology  
Department of General Surgery and Urology  
Jordan University of Science and Technology  
P.O. Box: 3030  
Irbid 22110, Jordan  
Phone: (+962) 27201000 Ext: 40605  
Email: banihani@just.edu.jo

Last updated: December 16, 2022